Suppression of experimental atherosclerosis by the Ca++-antagonist lanthanum. Possible role of calcium in atherogenesis.
about
Atherosclerosis. I. A leiomyoproliferative disease of the arteries resulting from breakdown of the endothelial barrier to potent blood growth factors. II. Perspectives in atheroprophylaxis.Lanthanum chloride suppresses oxysterol-induced ECV-304 cell apoptosis via inhibition of intracellular Ca(2+) concentration elevation, oxidative stress, and activation of ERK and NF-κB signaling pathways.Exposure, metabolism, and toxicity of rare earths and related compounds.Cholesterol enrichment increases basal and agonist-stimulated calcium influx in rat vascular smooth muscle cells.Calcium/calmodulin-mediated action of calcitonin on lipid metabolism in rats.Nifedipine increases cholesteryl ester hydrolytic activity in lipid-laden rabbit arterial smooth muscle cells. A possible mechanism for its antiatherogenic effect.Hypothesis: etiology of atherosclerosis and osteoporosis: are imbalances in the calciferol endocrine system implicated?Age-related medial elastocalcinosis in arteries: mechanisms, animal models, and physiological consequences.Calcium antagonists: pharmacologic agents in search of new clinical indications.The dual-effects of LaCl₃ on the proliferation, osteogenic differentiation, and mineralization of MC3T3-E1 cells.Troglitazone and pioglitazone attenuate agonist-dependent Ca2+ mobilization and cell proliferation in vascular smooth muscle cells.Aneurysm of the rabbit common carotid artery induced by periarterial application of calcium chloride in vivo.Effects of diltiazem on suppression and regression of experimental atherosclerosis.Calcium channel blocker nilvadipine, but not diltiazem, inhibits ocular inflammation in endotoxin-induced uveitis.Study on the performance enhancing effect of rare earth elements in growing and fattening pigs.
P2860
Q33445200-9CFDE6DF-565D-40E2-A24E-1FA2538827CCQ33832399-08A6C99B-54A8-4602-8B44-30C4B338D9B0Q34062960-4757009C-7764-47CB-8495-CE645796775DQ34213606-BCD5477B-03E7-4E9E-AEA0-5F68CB7DC6A4Q34555945-A7FBEC97-68BC-4E1E-B72B-CA7CB976BE5BQ34627457-0B4E3696-1007-4EE9-9A0B-F9BA95CA6D3AQ35552319-E73A6732-1D3C-44CE-9D71-B11F739B4962Q37261115-96C7910A-A248-4D03-938C-1BCBC4BD91D7Q38144615-578368D0-C33E-4594-AF00-5110CC68CE8BQ39298806-56C35BE0-99F0-46BC-B386-854566AF8202Q40923713-ADF97516-7B70-41B8-AFCA-2EE18B3A051BQ41016705-945396D0-C8F1-469B-8E47-85833B75BA74Q41564881-FF6D657C-AB83-420F-9029-6DD74A4F31E3Q42770007-46372A74-7857-4474-B56E-415AF11C0F08Q43784884-EB2C49CA-90CB-4D69-927C-9B4DE5C17125
P2860
Suppression of experimental atherosclerosis by the Ca++-antagonist lanthanum. Possible role of calcium in atherogenesis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 1980
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Suppression of experimental at ...... e of calcium in atherogenesis.
@en
Suppression of experimental at ...... e of calcium in atherogenesis.
@nl
type
label
Suppression of experimental at ...... e of calcium in atherogenesis.
@en
Suppression of experimental at ...... e of calcium in atherogenesis.
@nl
prefLabel
Suppression of experimental at ...... e of calcium in atherogenesis.
@en
Suppression of experimental at ...... e of calcium in atherogenesis.
@nl
P2093
P2860
P356
P1476
Suppression of experimental at ...... e of calcium in atherogenesis.
@en
P2093
P2860
P304
P356
10.1172/JCI109783
P407
P577
1980-05-01T00:00:00Z